NiCE (Nasdaq: NICE) today announced that NiCE Cognigy, a global leader in AI-first customer experience solutions, has been ...

Noticing a receding hairline? You’re not alone — and thanks to years of research, effective treatments are within reach. Male ...

The Guillain-Barre Syndrome Diagnostics Market is driven by the rising incidence of infections like Zika and aging populations, necessitating advanced diagnostics such as electromyography and nerve ...

Your skin is in a constant state of reinvention. Every month, your body sheds and regenerates its entire outer layer—a complete turnover powered by tiny, tireless stem cells. These same cells spring ...

Hair loss can be frustrating at any age, so when your strands start to look more sparse or your hair begins to lose its overall thickness, it’s normal to seek out hair care products that can help slow ...

Carley Millhone is a writer and editor based in the Midwest who covers health, women's wellness, and travel. Her work has appeared in publications like SELF, Greatist, and PureWow. Nick Blackmer is a ...

These top-rated hair growth treatments are loved by shoppers and can help with reducing shedding and supporting hair health, and they start at just $10. This concentrated serum supports hair health to ...

If you’ve ever struggled with stubborn acne, prominent signs of aging, or dark spots that just won’t fade, you may already be familiar with tretinoin—a prescription-strength topical medication that ...

This article was created in partnership with iRestore. All selections and source material were provided by iRestore. If you’re experiencing hair thinning or balding, iRestore hair growth systems are ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Lam Research is rated a Buy with a revised price target of $178, reflecting a 14% upside and market outperformance. Lam Research delivered strong FQ1 2026 results: 28% revenue growth, 47% EPS growth, ...